Lipocine (LPCN) News
NASDAQ: LPCNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.48-0.02 (-1.33%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LPCN news summary
We found 3 recent headlines mentioning Lipocine (LPCN): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, PR Newswire. For price context, LPCN is down 1.33% at $1.48. The most recent story, "Lipocine Inc. Reports Third Quarter of 2026 Financial Results and Initiates Phase 3 BLOOM Study", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Lipocine headlines
- Lipocine Inc. Reports Third Quarter of 2026 Financial Results and Initiates Phase 3 BLOOM StudyLipocine Inc. reported its financial results for the third quarter ended September 30, 2026. The company recognized total revenue of $2.3 million during the quarter, compared to $115,000 during the…Nasdaq
- Lipocine Announces Financial Results for the Third Quarter of 2026SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results…PR Newswire
- Here's Why You Should Add LPCN Stock to Your Portfolio NowLipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.NasdaqLPCN, ALNY, AMRN, ALDX